<DOC>
	<DOCNO>NCT01660022</DOCNO>
	<brief_summary>A Phase I Study investigate safety , tolerability &amp; pharmacokinetics co-administered single dos OZ439 Piperaquine healthy subject .</brief_summary>
	<brief_title>Safety Tolerability &amp; Pharmacokinetics Co-administered Single Doses OZ439 &amp; Piperaquine Healthy Subjects</brief_title>
	<detailed_description>Placebo-controlled , double-blind , five-cohort , 2-period ( per cohort ) dose-escalation study . For subject , study include screen evaluation ( within 21 day 1st dose ) , dose 2 separate occasion ( Period 1 Period 2 ) follow-up visit ( 6 week follow final dose ) . Within cohort , subject randomise two sequence receive OZ439 Period 1 OZ439 plus piperaquine Period 2 ( sequence 1 , 8 subject ) OZ439-matching placebo Period 1 OZ439/piperaquine match placebos Period 2 ( sequence 2 , 4 subject ) . Safety tolerability evaluate : Physical examination , ECG assessments include full baseline match profile ECG tracing , vital sign , laboratory evaluation , particular liver function test adverse event .</detailed_description>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Healthy male &amp; female , 1855 year old BMI 18 30kg/m2 ; total body weight &gt; 50kg Healthy , determine prestudy medical history , physical examination vital sign , 12 Lead ECG Females nonchildbearing potential . Males must agree use double barrier method contraception Lab test screen within reference range Any condition could affect drug absorption , e.g . gastrectomy , diarrhea Clinically relevant abnormality ECG Family history sudden death congenital prolongation QTc interval History symptomatic cardiac arrhythmia clinically relevant bradycardia Electrolyte disturbances History drug alcohol abuse , tobacco user Participation evaluation drug 3 month study Administration ANY systemic medication/herbal product within 14 day first dose study drug . unaccustomed strenuous exercise within 7 day study visit Alcohol consumption within 24 hour study visit Consumption fruit juice food contain grapefruit within 7 day Positive test HIV1 , HBsAg HCV Positive urine drug screen Screening admission Severe allergies/multiple drug allergy Volunteers donate blood experienced significant blood loss within 90 day screen Hemoglobin low limit reference range Clinically relevant abnormal lab value indicative physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Volunteers</keyword>
</DOC>